NeoStem, Inc. (NYSE: NBS; Stock Twits: $NBS) is engaged in the development and manufacturing of cell-based therapies in the U.S.
NeoStem, continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift occurring in medicine. We anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy industry.
In this interview, Dr. Robin Smith, CEO of NeoStem and Chairman and President of the Stem for Life Foundation discusses a range of topics including regenerative medicine, stem cell research, the Vatican's involvement with Neostem, and Neostem's potential in developing countries: